Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR)

Jasleen Minhas1, Sai Prasanna Narasimal1, Todd M. Bull2, Teresa De Marco3, John Wesley McConnell4, Matthew R. Lamm5, Thenappan Thenappan6, Jeremy P. Feldman7, Jeffrey S. Sager8, David B. Badesch2, John J. Ryan9, Daniel C. Grinnan11, Dianne Zwicke11, Evelyn M. Horn12, Jean M. Elwing12, John E. Moss14, Michael Eggert15, Oksana A. Shlobin16, Robert P. Frantz17, Sonja D. Bartolome18, Stephen C. Mathai19, Sula Mazimba20, Steven C. Pugliese1 and Nadine Al-Naamani1; on behalf of the PHAR investigators*

1Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, USA; 2Division of Pulmonary Sciences & Critical Care, University of Colorado, Denver, CO, USA; 3Division of Cardiology, University of California, San Francisco, CA, USA; 4Norton Healthcare, Louisville, KY, USA; 5Division of Pulmonary and Critical Care Medicine, Louisiana State University, New Orleans, LA, USA; 6Division of Cardiology, University of Minnesota, Minneapolis, MN, USA; 7Division of Pulmonary and Critical Care Medicine, Arizona Pulmonary Specialists, Phoenix, AZ, USA; 8Division of Pulmonary and Critical Care Medicine, Cottage PH center, Santa Barbara, CA, USA; 9Division of Cardiology, University of Utah, Salt Lake City, UT, USA; 10Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, USA; 11Division of Cardiology, Aurora Cardiovascular Services, Milwaukee, WI, USA; 12Division of Cardiology, Well Conrell Medicine, New York City, NY, USA; 13Division of Pulmonary and Critical Care Medicine, University of Cincinnati, Cincinnati, OH, USA; 14Department of Pulmonary Medicine and Division of Critical Care, Mayo Clinic, Jacksonville, FL, USA; 15Division of Pulmonary and Critical Care Medicine, Sentara Hospital, Norfolk, VA, USA; 16Division of Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Advanced Lung Disease and Transplant, Falls Church, VA, USA; 17Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA; 18Division of Pulmonary and Critical Care Medicine, University of Texas, Southwestern Medical Center, Dallas, TX, USA; 19Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 20Division of Cardiology, University of Virginia Health System, Charlottesville, VA, USA

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, morbid, potentially curable subtype of pulmonary hypertension that negatively impacts health-related quality of life (HRQoL). Little is known about differences in HRQoL and hospitalization between CTEPH patients and idiopathic pulmonary arterial hypertension (IPAH) patients. Using multivariable linear regression and mixed effects models, we examined differences in HRQoL assessed by emPHasis-10 (E10) and SF-12 between CTEPH and IPAH patients in the Pulmonary Hypertension Association Registry, a prospective multicenter cohort of patients newly evaluated at a Pulmonary Hypertension Care Center. Multivariable negative binomial regression models were used to estimate incidence rate ratios (IRR) for hospitalization amongst the two groups. We included 461 IPAH patients and 169 CTEPH patients. Twenty-one percent of CTEPH patients underwent pulmonary thromboendarterectomy (PTE) before the end of follow-up. At baseline, patients with CTEPH had significantly worse HRQoL (higher E10 scores) (ß 2.83, SE 1.11, p = 0.01); however, differences did not persist over time. CTEPH patients had higher rates of hospitalization (excluding the hospitalization for PTE) compared to IPAH patients after adjusting for age, sex, body mass index, WHO functional class and six-minute walk distance (IRR 1.66, 95%CI 1.04–2.65, p = 0.03). CTEPH patients who underwent PTE had improved HRQoL as compared to those who were medically managed, but patients who underwent PTE were younger, had higher cardiac outputs and greater six-minute walk distances. In this large, prospective, multicenter cohort, CTEPH patients had significantly worse baseline HRQoL and higher rates of hospitalizations than those with IPAH. CTEPH patients who underwent PTE had significant improvements in HRQoL.

*Details of PHAR investigators are given in Appendix 1.

Corresponding author:
Nadine Al-Naamani, 3600 Spruce Street, 9045 Gates Building, Philadelphia, PA 19104, USA.
Email: Nadine.al-naamani@pennmedicine.upenn.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by remodeling of the pulmonary arteries resulting from acute and recurrent pulmonary emboli with subsequent development of a pulmonary vasculopathy and elevated pulmonary artery pressures resulting in right heart dysfunction. CTEPH leads to functional impairment and negatively impacts health-related quality of life (HRQoL).1–3 Surgical treatment with pulmonary thromboendarterectomy (PTE) remains the mainstay of treatment for patients eligible for this procedure; however, 20 to 40% of CTEPH patients have inoperable disease or are not surgical candidates for other reasons.4 One-third of those who undergo PTE still have residual disease.5,6 Medical therapies primarily used to treat pulmonary arterial hypertension (PAH) are also used to treat patients with CTEPH; however, the role of medical treatment with or without PTE is not well defined. At the time of this analysis, riociguat remains the only FDA approved therapy for CTEPH.7

In contrast to CTEPH, medical therapies have a well-established role in the treatment of PAH with several FDA-approved drug classes. Despite some improvement with medical therapy, patients with PAH continue to experience significantly worse HRQoL than the general U.S. population. Additionally, patients with PAH have considerably higher rates of health care utilization, including up to four times the cost of matched controls, both before and after their diagnosis.8–10 Clinical studies often group the diagnoses of idiopathic PAH (IPAH) and CTEPH,11,12 and often vasodilator therapies used in CTEPH are based on extrapolations from PAH.13 However, there are limited data assessing patient-reported outcomes in CTEPH and comparing them to other PAH patients.14 The differences in pathogenesis, treatments and outcomes between these patient populations are important to define in a large generalizable population. IPAH is a common subtype of PAH.15,16 Among patients with PAH, those with IPAH are most likely to be treated with anticoagulation.17 This is likely due to contraindications to anticoagulation (such as liver disease, cytopenias, etc.) in other PAH subtypes.

We sought to investigate the differences in HRQoL and hospitalizations between patients with CTEPH and IPAH using data from the Pulmonary Hypertension Association Registry (PHAR) – a large, prospective multicenter cohort of pulmonary hypertension patients in the United States.

Methods

Study sample

The PHAR enrolls patients with PAH or CTEPH who were newly evaluated at one of >50 Pulmonary Hypertension Care Centers in the U.S. The registry began enrollment in 2015 with inclusion and exclusion criteria that have been previously described.18 For this analysis, we included adult patients (>18 years of age) with CTEPH or IPAH enrolled in the registry between January 2015 (inception of registry) and September 2019. This end date of enrollment was chosen to provide at least six months of follow-up before COVID-19-related shutdowns. Patients with both prevalent and incident diagnoses of either CTEPH or IPAH within six months of enrollment were included. CTEPH patients who had already undergone PTE before enrollment in the registry (n = 5) were excluded. All subjects were censored at the time of their last follow-up or March 1st, 2020 (chosen to avoid the impact of COVID-19 shutdown).

Clinical variables

After providing informed consent, demographics, clinical and social history, measurements of exercise performance and hemodynamics via right heart catheterizations were recorded at an initial visit for each patient. Patients were then followed at approximately six-month intervals. At each subsequent visit, patients provided updated demographics, social histories and reported all-cause hospitalizations since their last visit; however, the reason for hospital admission is not recorded in PHAR. Patients also reported symptoms and filled out HRQoL questionnaires described below. In addition, each participating site tracked outcomes, including PTE, lung transplantation and death.19 At the time of analysis, the registry had not yet started collecting data on pulmonary balloon angioplasty (BPA).

Study outcomes

HRQoL was assessed at the initial visit and longitudinally at all follow-up visits using two questionnaires: the medical outcome short form-12 (SF-12), an abbreviated version of the Medical Outcome Study Short Form-36, and the emPHasis-10 (E10), a pulmonary hypertension specific instrument. The SF-12 consists of a physical component score and mental component score. Each component has scores ranging from 0 to 100, with higher scores, indicating...
better HRQoL.\textsuperscript{20,21} The E10 score ranges from 0 to 50 with lower scores, indicating better HRQoL.\textsuperscript{22}

**Statistical analysis**

Baseline patient characteristics were summarized using descriptive statistics: numbers and percentages, mean and standard deviations and median and interquartile ranges, as appropriate.

Multivariable linear regression models were used to assess baseline differences in HRQoL scores in the CTEPH group compared to those with IPAH. These models were adjusted for \textit{a priori} selected potential confounders which included age, sex, body mass index (BMI), baseline six-minute walk distance and their baseline World Health Organization (WHO) functional class. These variables were selected because of their known impact on HRQoL and as surrogates for disease severity. We conducted a sensitivity analysis without the surrogate measures of disease severity (WHO functional class and six-minute walk distance) to confirm that our findings were not driven solely by severity of disease. For longitudinal data, mixed effects generalized linear models with random intercept and slopes were fitted to account for the repeated measures of HRQoL over time. These models were adjusted for the same variables, as above and interaction terms for PTE status with time and six-minute walk distance were added to account for the impact of PTE. Negative binomial regression models with an offset for time were used to determine the incidence rate ratios for hospitalization among patients with IPAH and CTEPH, adjusting for PTE status, age, sex, BMI, six-minute walk distance and WHO functional class. For this analysis, admission for PTE was not considered as a hospitalization event. We conducted a sensitivity analysis where we excluded CTEPH patients who underwent PTE from the hospitalization analysis to confirm our findings were not secondary to the PTE. Given that race is a social construct, the primary hypothesis for this study did not focus on exploring racial differences among groups of disease. Additionally, we found no scientific justification to hypothesize that race alone should impact on HRQoL or hospitalizations; therefore, we did not include race as a covariate in our models.\textsuperscript{23} Additionally, we ran a sensitivity analysis limiting the dataset to incident IPAH and CTEPH patients (diagnosed within six months of enrollment into the PHAR).

Within the CTEPH subgroup, unadjusted mixed effects generalized linear regression models were used to compare repeat measures of HRQoL between patients who had undergone PTE versus those who were medically managed. Adjusted models for repeat measures were not performed due to the overall small number of patients who underwent PTE in this cohort. All statistical analyses were performed in R version 4.0.4 and RStudio version 1.4.1106.

**Results**

**Clinical characteristics**

There were 1361 patients enrolled in PHAR by September 2019, of whom 630 met criteria for inclusion in our analysis (Fig. 1). Of these, 73\% had IPAH, and 27\% had CTEPH. Table 1 details the baseline characteristics of the study cohort. At the time of enrollment, patients with IPAH were younger with a mean age of 55 years, more likely to be female (76\%) and majority non-Hispanic white (71\%).

Fig. 1. Flow diagram for study participants.
### Table 1. Patient characteristics of the cohort at time of enrollment in PHAR.

|                      | IPAH N = 461 | CTEPH N = 169 |
|----------------------|--------------|---------------|
| **Age**              | 55 ± 17      | 58 ± 16       |
| **Female sex**       | 348 (76.0)   | 84 (50.0)     |
| **BMI (kg/m²)**      | 31.0 ± 7.8   | 31.7 ± 8.5    |
| **Race/ethnicity**   |              |               |
| Non-Hispanic white   | 328 (71.1)   | 111 (65.7)    |
| African American     | 52 (11.3)    | 41 (24.3)     |
| Hispanic             | 47 (10.2)    | 9 (5.3)       |
| Asian                | 9 (2.0)      | 0 (0.0)       |
| Other/multi-racial   | 25 (5.4)     | 8 (4.7)       |
| **Highest level of education (n = 628)** |              |               |
| Some Schooling       | 242 (53.0)   | 88 (52.7)     |
| Completed high school| 172 (37.6)   | 67 (40.1)     |
| College or graduate studies | 43 (9.4) | 12 (7.2) |
| **Household Income (n = 508)** |              |               |
| <$25,000             | 100 (26.7)   | 30 (23.1)     |
| $25,000–50,000       | 84 (22.5)    | 34 (26.2)     |
| $50,000–$75,000      | 58 (15.5)    | 20 (15.4)     |
| $75,000–$100,000     | 41 (11.0)    | 23 (17.7)     |
| >$100,000            | 91 (24.3)    | 23 (17.7)     |
| **Employment (n = 632)** |              |               |
| Homemaker/retired    | 320 (69.7)   | 106 (63.1)    |
| Employed (Full or part time) | 126 (27.5) | 60 (35.7) |
| Unemployed           | 13 (2.8)     | 2 (1.2)       |
| **Marital status**   |              |               |
| Married/living with partner | 272 (59.0) | 95 (56.2) |
| Widowed/divorced/separated | 99 (21.5) | 41 (24.3) |
| Never married        | 78 (16.9)    | 30 (17.8)     |
| Did not answer       | 12 (2.6)     | 3 (1.8)       |
| **Right heart catheterization hemodynamics** |              |               |
| RA pressure (mm Hg)  | 10 [6, 14]   | 9 [7, 12]     |
| Mean PA pressure (mm Hg) | 51 [42, 60] | 45 [37, 53] |
| PCWP (mm Hg)         | 11 [7, 14]   | 11 [8, 16]    |
| Cardiac output (L/min) | 4.2 [3.2, 5.1] | 4.5 [3.6, 5.4] |
| Cardiac index (L/min/m²) | 2.1 [1.7, 2.6] | 2.3 [1.9, 2.7] |
| PVR (Wood units)     | 9.7 [6.7, 14.0] | 7.9 [5.4, 10.6] |
| Incident case        | 233 (50.7)   | 85 (50.9)     |
| **Pulmonary vasodilators** |              |               |
| PDE5 inhibitors      | 200 (43.4)   | 7 (4.1)       |
| ERA                  | 160 (34.7)   | 8 (4.7)       |
| Parenteral prostacyclin | 78 (16.9) | 1 (0.6)       |
| Inhaled prostacyclin | 5 (1.1)      | 0 (0.0)       |
| Selexipag            | 11 (2.4)     | 2 (1.2)       |
| Riociguat            | 12 (2.6)     | 37 (21.9)     |
| Any combination      | 176 (38.2)   | 6 (3.6)       |
| Oxygen supplementation | 140 (30.4) | 38 (22.5)     |
| Anticoagulation at presentation | 79 (17.1) | 91 (53.8) |
| Anticoagulation on follow-up | 160 (34.7) | 160 (94.7) |
| **WHO functional class** |              |               |
| I                    | 50 (11.7)    | 9 (6.0)       |
| II                   | 144 (33.8)   | 66 (43.7)     |
| III                  | 206 (48.4)   | 66 (43.7)     |
| IV                   | 26 (6.1)     | 10 (6.6)      |
| 6MWD (m)             | 345 ± 141    | 336 ± 118     

(continued)
Hospitalizations

Of the 630 patients included in our study, 515 patients had at least one subsequent follow-up visit. During 1585 person-years of follow-up, there were 939 hospitalizations recorded. Patients with CTEPH had a higher incidence rate ratio of all-cause hospital admissions than patients with IPAH (IRR 1.66, 95%CI 1.04–2.65, p = 0.035) after adjustment for age, sex, BMI, six-minute walk distance, WHO functional class and PTE status (Fig. 4). In sensitivity analysis excluding CTEPH patients who underwent PTE, CTEPH patients were again noted to have increased incidence rates of hospitalizations as compared to IPAH patients (IRR 1.90, 95% CI 1.08–3.40, p = 0.027).

CTEPH subgroup analysis

In PHAR, 63% of patients with CTEPH were referred for surgical evaluation at enrollment. By the end of follow-up,
22% had undergone PTE and 78% were managed medically. Mean age was 59 years and majority females (69%) among all patients who were medically managed through-out and did not undergo PTE (Table 2). The CTEPH patients who underwent PTE were younger with a mean age of 54 years and more likely to be male (62%). There were no differences in levels of education, household income, employment, or marital status between the two groups (Table 2).

When compared to those that were medically managed, patients who underwent PTE had a higher cardiac output (4.7 vs. 4.3 L/min) and higher E10 scores (worse HRQoL, 29 vs. 24). However, the patients who underwent PTE were less likely to present in WHO functional class IV (3% vs. 6%) and had greater six-minute walk distances (425 vs. 335 m) in comparison to patients who were managed medically. There were no differences in cardiac indices, right atrial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure between the groups and both were most frequently treated with riociguat (Table 2).

Patients who underwent PTE had a decrease in their E10 scores postoperatively indicating improved HRQoL (Fig. 5). Unadjusted mixed effects models showed that patients who underwent PTE had lower E10 scores and higher SF-12 physical component scores, both indicative of better HRQoL (Fig. 6). There were no differences in SF-12 mental component scores between the two subgroups.

**Discussion**

In a large multicenter prospective cohort of patients with IPAH and CTEPH across the US, patients with CTEPH at enrollment were older, with better hemodynamics (lower pulmonary artery systolic pressure and pulmonary vascular resistance) but worse HRQoL when compared to patients with IPAH after adjustment for baseline variables; however, the difference in HRQoL did not persist over time. Patients with CTEPH had higher hospitalization rates (after excluding hospitalization for PTE) than patients with IPAH. Among CTEPH patients, those who eventually underwent PTE were younger, male, with a higher cardiac output and better six-minute walk distance than those who were medically managed. In addition, patients with CTEPH who underwent PTE had improvement in their HRQoL.

Pulmonary hypertension is a rare debilitating disease that negatively impacts the quality of life of patients and their caregivers. In addition to hemodynamic measurements, laboratory biomarkers and exercise testing, there has been increased recognition of the importance of incorporating patient-centered outcomes into management decisions and clinical trial design. Several studies have demonstrated a strong correlation between patient-reported HRQoL and outcomes such as the six-minute walk distance, hospitalizations and survival in pulmonary hypertension. Studies exploring differences in HRQoL between patients with CTEPH and IPAH have mixed results with some finding no difference and others showing CTEPH patients having worse HRQoL. The results from this study demonstrate that patients with CTEPH have higher E-10 scores (worse HRQoL) at referral to a Pulmonary Hypertension Care Center as compared to patients with IPAH, but these differences do not persist over time in a large prospective multicenter cohort. While the differences in scores at baseline is statistically significant, it is smaller than the minimally clinically important difference reported for E-10 scores, which is approximately a six-point change, so the clinical implications of the difference in scores remain to be determined. Among CTEPH patients, similar to what has been previously reported, this study found that patients who undergo PTE have significant improvement in their HRQoL, and the improvement in scores may be more significant in patients without residual disease post-PTE.

The worse HRQoL observed in CTEPH patients at referral was not explained by older age as compared to IPAH patients; however, older age may be associated with increased co-morbid conditions, which were not available for us to account for. Over time, with treatment, both groups had similar HRQoL scores. The improvement in the CTEPH group may be driven by improved HRQoL scores in the subgroup of CTEPH patients who underwent PTE. In contrast, medically managed patients with CTEPH and IPAH patients continued to have similar HRQoL.

Since most patients with CTEPH in this cohort were medically managed, this may have biased our results towards the null. While this study found differences in E-10 scores, no differences were detected in SF-12 scores among patients with IPAH versus those with CTEPH. The E-10 is a PH-specific instrument and thus may be a more sensitive tool to measure HRQoL in these patient populations.
|                           | Medical management | PTE group |
|---------------------------|--------------------|-----------|
| **N**                     | 133                | 36        |
| **Age**                   | 59 ± 16            | 54 ± 15   |
| **Female sex**            | 69 (52.0)          | 64 (38.0) |
| **BMI (kg/m²)**           | 31.3 ± 8.0         | 30 ± 7.7  |
| **Race/ethnicity**        |                    |           |
| Non-Hispanic white        | 85 (64)            | 26 (72)   |
| African American          | 34 (25.6)          | 7 (19.4)  |
| Hispanic                  | 8 (6.0)            | 1 (2.8)   |
| Asian                     | 0 (0.0)            | 0 (0.0)   |
| Other/multi-racial        | 4 (3.0)            | 2 (5.6)   |
| **Highest level of education** |                |           |
| Some schooling            | 70 (53)            | 18 (51)   |
| Completed high school     | 52 (39)            | 15 (43)   |
| College or graduate studies | 10 (8)          | 2 (6)     |
| **Household income**      |                    |           |
| <$25,000                  | 24 (24)            | 6 (21)    |
| $25,000–50,000            | 25 (25.7)          | 8 (28)    |
| $50,000–$75,000           | 12 (11.9)          | 8 (27.6)  |
| $75,000–$100,000          | 21 (20.8)          | 2 (6.9)   |
| >$100,000                 | 18 (17.6)          | 5 (17.2)  |
| **Employment**            |                    |           |
| Homemaker/retired         | 85 (64.4)          | 21 (58.3) |
| Employed (Full or part time) | 45 (34.1)     | 15 (41.7) |
| Unemployed                | 2 (1.5)            | 0 (0.0)   |
| **Marital status**        |                    |           |
| Married/living with partner | 77 (57.9)     | 18 (50)   |
| Widowed/divorced/separated | 32 (24.1)   | 9 (25)    |
| Never married             | 21 (15.8)          | 9 (25)    |
| Did not answer            | 3 (2.3)            | 0 (0.0)   |
| **Right heart catheterization hemodynamics** | | |
| RA pressure (mm Hg)       | 9 [6, 13]          | 10 [7, 12] |
| Mean PA pressure (mm Hg)  | 45 [37, 54]       | 45 [42, 51] |
| PCWP (mm Hg)              | 11 [8, 16]        | 11 [7, 14] |
| Cardiac output (L/min)    | 4.3 [3.52, 5.4]   | 4.7 [4.2, 5.5] |
| Cardiac index (L/min/m²)  | 2.22 [1.88, 2.56] | 2.29 [1.90, 2.80] |
| PVR (Wood units)          | 8 [5, 11]         | 7 [5, 10] |
| **Pulmonary vasodilators**|                    |           |
| PDE5 inhibitors           | 7 (5.3)            | 0 (0.0)   |
| ERA                       | 8 (6.0)            | 0 (0.0)   |
| Parenteral prostaclenin   | 1 (0.8)            | 0 (0.0)   |
| Inhaled prostaclenin      | 0 (0.0)            | 0 (0.0)   |
| Selexipag                 | 2 (1.5)            | 0 (0.0)   |
| Riociguat                 | 31 (23.3)          | 6 (16.7)  |
| Any combination           | 6 (4.5)            | 0 (0.0)   |
| Oxygen supplementation    | 29 (21.8)          | 9 (25.0)  |
| Anticoagulation at presentation | 61 (45.9) | 30 (83.3) |
| Anticoagulation on follow-up | 125 (94.0) | 35 (97.2) |
| **WHO functional class**  |                     |           |
| I                         | 9 (7.6)            | 0 (0.0)   |
| II                        | 55 (46.6)          | 11 (33.3) |
| III                       | 45 (38.1)          | 21 (63.6) |
| IV                        | 9 (7.6)            | 1 (3.0)   |
| **6MWD (m)**              | 335 ± 138          | 425 ± 82  |
| **Health-related quality of life measures** | | |
| emPHasis-10               | 24 ± 12            | 29 ± 11   |
| SF-12 physical component  | 34 ± 7             | 35 ± 6    |
| SF-12 mental component    | 49 ± 8             | 47 ± 9    |

Note: Data are presented as N (%), mean ± standard deviation, median [Interquartile Range].

6MWD: six-minute walk distance; RA: right atrial; PA: pulmonary artery; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; SF: short form; PDE5: phosphodiesterase-5; ERA: endothelin receptor antagonists.
PTE is a potentially curative procedure in CTEPH and is recommended as the treatment of choice in this population by the European Society of Cardiology/European Respiratory Society expert consensus guidelines. Successful PTE has been associated with lower right atrial pressure, higher cardiac index, better WHO functional class and improved survival. In the overall population of patients with CTEPH, it is estimated that PTE is feasible in 63–76% of patients and 71–88% of those who are deemed operable undergo the procedure. At their initial assessment at a Pulmonary Hypertension Care Center, only 63% of patients with CTEPH were referred for surgical evaluation for PTE. The relatively low rate of referral to PTE at enrollment in the PHAR is likely a reflection of their incident case status and referrals often occur after evaluation at one of the Pulmonary Hypertension Care Centers. Of all the CTEPH patients in our cohort, 78% were medically managed, and only 22% underwent PTE. An additional five patients had undergone PTE prior to enrollment in the PHAR and were excluded from our analysis. In our cohort, rates of PTE were significantly lower presumably because patients either declined surgery or had factors that deemed them unsuitable for surgery – such as co-morbidities or distribution of clots on imaging. Reasons for no surgical referral and reasons for no PTE after surgical referral were not recorded in the PHAR. Due to the low number of patients who underwent PTE in this cohort, we were unable to examine how hospitalization rates change post PTE.

Pulmonary hypertension is associated with higher health care utilization and costs. Studies of patients with CTEPH found that these patients have up to six times
higher inpatient and outpatient costs and overall health care utilization than matched controls.\textsuperscript{8,37} However, we are not aware of prior studies comparing hospitalization rates between IPAH and CTEPH. In our cohort, patients with CTEPH had higher hospitalization rates than those with IPAH (excluding the hospitalization for PTE) even after adjusting for patient demographics and disease severity. It is possible that this may be a reflection of the higher rate of associated co-morbidities in this patient cohort, bleeding-related complications in patients with CTEPH or may include admissions for balloon pulmonary angioplasty, data for which were not collected in PHAR at the time of analysis.

This study has several limitations. Seven percent of patients in this registry were lost to follow-up. Based on the “real-world” registry protocol, patients were seen in follow-up “as clinically needed” in approximately six-month intervals, thus resulting in variable follow-up times for patients. However, this should not lead to a bias due to the non-differential nature of the missing data. Additionally, all of the previously presented longitudinal analyses incorporated patient follow-up times. Details of comorbid conditions and pulmonary vascular imaging were not recorded in the registry, limiting the assessment of surgical eligibility. Additionally, data on balloon pulmonary angioplasty were not collected in this cohort during the study period which limits our ability to investigate whether higher hospitalization rates among CTEPH patients could be partially attributable to patients undergoing balloon pulmonary angioplasty. Finally, the overall rates of PTE were lower in this cohort than those generally reported in the CTEPH population in prior publications and are likely reflective of “real-world” practice across pulmonary hypertension centers where PTE may not be readily accessible; however, we anticipate that the lower rates of PTE would have likely biased our results to the null. Data on the lack of surgical eligibility, patient refusal and balloon pulmonary angioplasty were not captured. To address some of these limitations, the PHAR began prospectively recording data on balloon pulmonary angioplasties starting in June 2020. Future studies will focus on the inclusion of these data for analyses.

In a large, multicenter, prospective cohort, patients with CTEPH were found to have significantly worse HRQoL at initial presentation to pulmonary hypertension specialty centers compared to patients with IPAH; however, these differences did not persist over time. CTEPH patients who underwent PTE experienced significant improvements in HRQoL. The worse baseline quality of life and higher hospitalization rate of CTEPH patients present an opportunity for improvement in clinical management of these patients.

**Acknowledgements**

The Pulmonary Hypertension Association Registry (PHAR) is supported by Pulmonary Hypertension Care Centers, Inc., a supporting organization of the Pulmonary Hypertension Association. The authors thank the other investigators, the staff, and particularly participants of the PHAR for their valuable contributions. A full list of participating PHAR sites and institutions can be found at www.PHAssociation.org/PHAR.

**Contributorship**

All authors have participated in the conceptualization, writing and interpretation of the content and have approved the final version of this article. Drs. Minhas, Narasimmal, Pugliese and Al-Naamani were involved in the data collection and analysis of this project.

**Guarantor**

Minhas and Al-Naamani are guarantors of the paper and take responsibility for the integrity of this work as a whole.

**Ethical Approval**

This study was approved by the University of Pennsylvania Institutional Review Board (#822830).

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH/NHLBI (grant number K23 HL141584 (NAN) and T32-HL007891 (JM)).

**ORCID iDs**

Jasleen Minhas \( \text{https://orcid.org/0000-0001-7864-6096} \)
Matthew R. Lammi \( \text{https://orcid.org/0000-0001-5125-1801} \)

**References**

1. Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. *Heart* 2012; 98: 1805–1811.
2. Darteville P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2004; 23: 637.
3. Mathai SC, Suber T, Khair RM, et al. Health-related quality of life and survival in pulmonary arterial hypertension. *Ann Am Thorac Soc* 2016; 13: 31–39.
4. Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. *Eur Respir Rev* 2017; 26: 160111.
5. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. *Eur Respir Rev* 2010; 19: 59–63.
6. Freed DH, Thomson BM, Berman M, et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. *J Thorac Cardiovasc Surg* 2011; 141: 383–387.
7. Ghofrani H-A, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med* 2013; 369: 319–329.
8. Said Q, Martin BC, Joish VN, et al. The cost to managed care of managing pulmonary hypertension. *J Med Econ* 2012; 15: 500–508.
9. Burke JP, Hunsche E, Régulier E, et al. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. *Am J Manag Care* 2015; 21(3 Suppl): s47–s58.

10. Anand V, Roy SS, Archer SL, et al. Trends and outcomes of pulmonary arterial hypertension-related hospitalizations in the United States: analysis of the Nationwide inpatient sample database from 2001 through 2012. *JAMA Cardiol* 2016; 1: 1021–1029.

11. Chen H, Taichman DB and Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. *Proc Am Thorac Soc* 2008; 5: 623–630.

12. Armstrong I, Billings C, Kiely DG, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. *BMC Pulm Med* 2019; 19: 67.

13. Hoepner MM. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. *Eur Respir Rev* 2015; 24: 272–282.

14. Favoccia C, Kempny A, Yorke J, et al. EmPHasis-10 score for the assessment of quality of life in various types of pulmonary hypertension and its relation to outcome. *Eur J Prevent Cardiol* 2018; 26: 1338–1340.

15. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. *J Am Coll Cardiol* 2013; 62(25 Suppl): D51–D59.

16. Prins KW and Thnappan T. World Health Organization Group I Pulmonary hypertension: epidemiology and pathophysiology. *Cardiol Clin* 2016; 34: 363–374.

17. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Circulation* 2014; 129: 57–65.

18. DesJardin JT, Kolaitis NA, Kime N, et al. Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: baseline results from the Pulmonary Hypertension Association Registry. *J Heart Lung Transplant* 2020; 39: 945–953.

19. Gray MP and Kawut SM. The Pulmonary Hypertension Association Registry: rationale, design, and role in quality improvement. *Adv Pulm Hypertens* 2018; 16: 185–188.

20. Ware J Jr, Kosinski M and Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996; 34: 220–233.

21. Loosman WL, Hoekstra T, van Dijk S, et al. Short-form 12 or short-form 36 to measure quality-of-life changes in dialysis patients? *Nephrol Dial Transplant* 2015; 30: 1170–1176.

22. Yorke J, Corris P, Gaine S, et al. emPHAsis-10: development of a health-related quality of life measure in pulmonary hypertension. *Eur Respir J* 2014; 43: 1106–1113.

23. Vyas DA, Eisenstein LG and Jones DS. Hidden in plain sight – reconsidering the use of race correction in clinical algorithms. *N Engl J Med* 2020; 383: 874–882.

24. Guillemin L, Armstrong I, Aldrighetti R, et al. Understanding the impact of pulmonary arterial hypertension on patients and carers lives. *Eur Respir Rev* 2013; 22: 535.

25. McGoon MD, Ferrari P, Armstrong I, et al. The importance of patient perspectives in pulmonary hypertension. *Eur Respir J* 2019; 53: 1801919.

26. Doward LC and McKenna SP. Defining patient-reported outcomes. *Value Health* 2004; 7 Suppl 1: S4–S8.

27. Schipper HCJ and Powell V. Definitions and conceptual issues. In: Spiker B (ed.) *Quality of life assessments in clinical trials*. New York: Raven Press, 1990, pp.11–24.

28. McCabe C, Bennett M, Doughty N, et al. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Chest* 2013; 144: 522–530.

29. Ivarsson B, Hesselstrand R, Rådegran G, et al. Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. *Chron Respir Dis* 2019; 16: 147997231887906.

30. Cole E, Armstrong I and Cutts K. Psychological differences between people with PAH, IPAH and CTEPH. *Eur Respir J* 2016; 48(suppl 60): PA2431.

31. Newham M, Buncik K, Abraham N, et al. CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. *Eur Respir J* 2020; 56: 1902096.

32. Borgese M, Badesch D, Bull T, et al. EmPHAsis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. *Eur Respir J* 2021; 57: 2000414.

33. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. *Ann Thorac Surg* 2003; 76: 1457–1464.

34. Galié N, Humbert M, Vachieri J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), *Int Soc Heart Lung Transplanti (ISHLT)* 2015; 46: 903–975.

35. Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. *Circulation* 2016; 133: 859–871.

36. Gall H, Hoepner MM, Richter MJ, et al. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. *Eur Respir Rev* 2017; 26: 160121.

37. Kirson NY, Birnbaum HG, Ivanova JJ, et al. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population. *Appl Health Econ Health Policy* 2011; 9: 377–387.

38. George MG, Schieb LJ, Ayala C, et al. Pulmonary hypertension surveillance: United States, 2001 to 2010. *Chest* 2014; 146: 476–495.

**Appendix 1. PHAR Investigators**

Abhijit Raval, MD, Amresh Raina, MD, Anna Hennes, MD, Bruce Andrus, MD, Charles Burger, MD, Corey Ventetuolo, MD, D. Dunbar Ivy, MD, Delphine Yung, MD, Eric Austin, MD, Eric Roberts, MD, Erika Berman-Rosenzweig, MD, Gautam Ramani, MD, Granthem Farr,
